CDC: 3.7% of U.S. Adults Use Cannabis Most Days to Sleep

Cannabis as a sleep aid is no longer a niche habit — it is a population-scale behavior the federal government can now put a number on. According to new CDC data circulated in mid-May 2026 and amplified by Marijuana Moment in its May 14 newsletter, roughly 3.7 percent of U.S. adults aged 18 and older report using cannabis products most days to help them fall asleep or stay asleep. Among adults aged 18 to 35, the figure rises to approximately 5.5 percent. The numbers are the clearest signal yet that the cannabis-for-sleep use case has crossed from anecdotal into one of the most common reasons Americans now reach for a cannabis product at all.

This article walks through what the CDC data shows, why it matters in a market increasingly defined by sleep-targeted products, and what consumers should weigh before adopting nightly cannabis use as a sleep aid. Readers shopping a sleep-leaning purchase can compare current menus across every legal market on Budpedia's cannabis dispensary directory — useful when you want to filter for CBN-stacked gummies or low-dose THC tinctures rather than guessing from the shelf.

What the New CDC Data Shows

The headline figures are drawn from CDC analysis of national health-survey data on adult cannabis use and reasons for use. The 3.7 percent of adults who report most-day cannabis use specifically for sleep translates to roughly 9.5 million Americans — a population the size of metropolitan Atlanta using cannabis as their primary sleep intervention. Among adults 18 to 35, the 5.5 percent figure is meaningfully higher, suggesting a generational pattern: younger adults are more likely to consider cannabis a default sleep tool than older cohorts who came of age under stricter prohibition.

The data also lands in a context that helps explain it. CDC's broader survey work in 2025 and early 2026 has documented persistent insomnia rates of around 14 percent among U.S. adults, with subjective sleep dissatisfaction much higher. Prescription sleep aids — most notably zolpidem and other "Z-drugs" — have seen regulatory caution grow over the past decade, with the FDA repeatedly tightening labels around residual next-day impairment, complex sleep behaviors and dependence. Against that backdrop, cannabis has become a perceived "natural" alternative for adults who do not want to take a benzodiazepine or a Z-drug night after night, even though the evidence base for cannabis as a long-term sleep intervention is far from settled.

It is worth being careful with what 3.7 percent actually represents. The figure tracks self-reported use frequency, not clinical insomnia diagnoses or sleep-tracker outcomes. It also does not parse out which cannabis products — THC-dominant flower, CBD tinctures, CBN gummies, or balanced formulations — are doing the work. What it does establish is that cannabis is being used as a sleep intervention at population scale, and any conversation about cannabis policy, product labeling, or clinical guidance now has to start from that fact.

Why the Product Market Has Been Reshaped Around Sleep

The cannabis industry has been chasing the sleep buyer since 2023, and the CDC data validates how big the addressable market really is. Sleep-focused stock-keeping units have been the fastest-growing category in many state markets over the past 18 months, with formulations stacking THC alongside CBN (cannabinol, often marketed as the "sleep cannabinoid"), CBD, and minor cannabinoids like CBG or THCV in micro-doses. Industry data from BDSA and Headset has consistently shown that "sleep" is the single largest stated reason for purchase among edible-buyers in mature markets — eclipsing pain, recreation, and anxiety.

Functional gummies dosed at 5–10 mg THC with 2–5 mg CBN are the prototypical sleep product, sold under labels from major multi-state operators and craft brands alike — our cannabis sleep stack guide walks through the dose ratios that show up most often on shelves. Tinctures with similar cannabinoid stacks have grown in parallel, often paired with botanicals like passionflower, valerian, or l-theanine in formulations that resemble traditional supplement marketing more than legacy cannabis branding. Vapes designed for short pre-bed sessions, with terpene profiles heavy in myrcene and linalool, complete the category.

What the CDC data signals is that this product strategy was not a marketing manufactured trend — it was an industry catching up to a use pattern that was already entrenched. The 5.5 percent young-adult figure also helps explain why cannabis brands are spending so much shelf space on sleep-coded packaging: the buyers most likely to anchor on sleep as their primary use case are exactly the demographic operators want to convert into long-term customers.

What the Science Says — and Doesn't Say — About Cannabis for Sleep

The clinical picture is messier than the market would suggest. Short-term studies generally find that THC reduces sleep-onset latency — meaning people fall asleep faster — and can suppress REM sleep, which some users describe as "dreamless" rest. CBD's effects on sleep at typical consumer doses are smaller and more inconsistent, with newer evidence pointing toward an indirect benefit through anxiety reduction rather than a direct sedative mechanism. CBN, the breakout cannabinoid of the sleep category, has limited human trial data, and most of the "CBN is sedating" framing in marketing comes from animal studies and small open-label series rather than placebo-controlled trials.

A 2026 study covered by Budpedia earlier this spring found that regular cannabis use disrupts sleep architecture over time, particularly reducing time spent in REM sleep — the stage most associated with memory consolidation and emotional processing. Other 2026 trials have found benefits for specific populations, including a clinical trial showing cannabis was non-inferior to lorazepam for short-term sleep onset in some patients. The honest read is that cannabis can shorten the time it takes to fall asleep for many users, particularly in the short term, but that nightly long-term use raises real questions about REM loss, tolerance escalation, and rebound insomnia when stopped.

Practical guidance from clinicians who treat sleep disorders tends to coalesce around the same advice: keep nightly THC doses low (5 mg or below), avoid increasing the dose to chase the same effect, and build in tolerance breaks to avoid REM suppression becoming chronic. The CDC's 3.7 percent figure tells us that a large slice of adults are running their own informal experiment with that protocol whether their doctor recommended it or not.

Key Takeaways

• New CDC data shows 3.7 percent of U.S. adults — roughly 9.5 million people — use cannabis most days as a sleep aid.
• The figure rises to 5.5 percent among adults 18 to 35, indicating a generational shift toward cannabis as a default sleep tool.
• Cannabis sleep products — particularly THC + CBN gummies and tinctures — are the fastest-growing edible category in mature state markets.
• Short-term studies find THC shortens sleep-onset latency but suppresses REM, raising questions about long-term nightly use.
• Clinicians generally recommend low nightly doses, deliberate tolerance breaks, and a conversation with a primary-care provider before relying on cannabis as a sole sleep intervention.

Cannabis can affect sleep architecture and is not a substitute for evaluation by a clinician for chronic insomnia. Explore cannabis news, find dispensaries, and join the community at Budpedia.